Cinclus Pharma Q1: Focus on upcoming pivotal study - Redeye

Redeye provides a research update following the Q1 report published by Cinclus earlier today. The report did not include any major surprises and was mostly in line with our expectations. All eyes are now on the forthcoming phase III study, set to be initiated in Q3 2025e.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110486/cinclus-pharma-q1-focus-on-upcoming-pivotal-study?utm_source=finwire&utm_medium=RSS